Dr Reddys Laboratories (RDY) Change in Receivables (2009)
Dr Reddys Laboratories (RDY) posted quarterly Change in Receivables of $26.0 million for Q4 2009, up 271.43% quarter-over-quarter from $7.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Change in Receivables (2009) Analysis & Trends
Dr Reddys Laboratories' Change in Receivables history runs 1 years deep, the most recent figure standing at $26.0 million for Q4 2009.
- In Q4 2009, Change in Receivables changed N/A year-over-year to $26.0 million; the TTM figure through Dec 2009 stood at -$23.8 million (changed N/A YoY), while the FY2026 annual figure was -$72.0 million, up 40.0% from the prior year.
- Change in Receivables for Q4 2009 stood at $26.0 million, up from $7.0 million in the prior quarter.
- The five-year high for Change in Receivables was $26.0 million in Q4 2009, with the low at $7.0 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 48.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | 26.00 Mn |
| Dec 31, 2009 | 26.00 Mn |
| Sep 30, 2009 | 7.00 Mn |
| Sep 30, 2009 | 7.00 Mn |
| Jun 30, 2009 | 12.00 Mn |
| Jun 30, 2009 | 12.00 Mn |